The global DEB treatment market is experiencing significant growth, driven by advancements in gene and cell therapies. With the recent FDA approval of Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for recessive DEB, the landscape is evolving rapidly.

For more details – https://www.reportprime.com/dystrophic-epidermolysis...

???????????? ???????????????????????? ????????????????????????????:

FDA Approvals: Zevaskyn and Vyjuvek offer new hope for patients.

Innovative Therapies: Gene and cell-based treatments leading the way.

???????????????????????????????? ????????????????????????:

Precision Medicine: Tailored treatments based on genetic profiles.

Regenerative Therapies: Stem cell and tissue engineering approaches gaining traction.

???????????? ???????????????????????????? ???????????? ???????????? ????????????????:

Visit our website: https://www.reportprime.com